For the nine months ended September 30, 2026, Harvard Apparatus Regenerative Technology reported a net loss of $4.8 million, a slight improvement from the $5.2 million loss in the prior year period. While product revenue increased to $785,000, the company continues to operate with a significant accumulated deficit of $111.3 million and highlights its dependence on future capital raises to continue as a going concern.
Harvard Apparatus Regenerative Technology CEO Junli He Buys $394K of Stock
Junli He, CEO, bought 368,630 shares of Harvard Apparatus Regenerative Technology, Inc. at $1.05 to $2.15 a share (average $1.07) in 2 transactions, worth $394K in total between Sep 11, 2026 and Sep 15, 2026. Shares held after the trade: 1,332,930 (+0.5%).
Harvard Apparatus Regenerative Technology Capital Raise of $2.84M
Harvard Apparatus Regenerative Technology closed a private placement of 2,703,727 shares of common stock at $1.05 per share for total proceeds of approximately $2.84 million. The transaction included a $717,911 debt-for-equity conversion by CEO Jerry (Junli) He, who cancelled outstanding bridge promissory notes in exchange for shares at the same offering price.